Organ Preservation Solutions Market

Organ Preservation Solutions Market Outlook (2025 to 2035)

The global organ preservation solutions market is expected to see substantial growth over the next decade, driven by increasing organ transplantation procedures, the rising prevalence of organ failure, and technological advancements in organ preservation methods. Worth USD 286.8 million in 2025, the valuation is expected to grow to about USD 574.7 million by 2035, at a consistent CAGR of 7.2% during the forecast period.

Organ preservation solutions play a crucial role in sustaining organ viability and function between procurement and transplantation. These strategies are of central importance in optimizing transplant success through the minimization of ischemic damage and expansion of the window of safe preservation, particularly for organs like kidneys, livers, hearts, lungs, and pancreas.

With organ transplantation increasingly becoming a life-saving therapy and a commonplace intervention in most nations, there has never been a greater demand for sophisticated and efficient preservation strategies. One of the key drivers of growth is the increase in diabetes, cardiovascular disease, and liver cirrhosis, most of which usually result in end-stage organ failure.

Governments and healthcare systems around the world are, in response, increasingly allocating funds to transplant programs and infrastructure. This is through donor registry expansion, cross-border organ exchange facilitation, and enhancement of the organ preservation and transportation chain.

In addition, the development of new preservation technologies, such as hypothermic and normothermic machine perfusion, is improving organ storage effectiveness. These methods provide continuous perfusion of preservation solutions through the organ, with continued metabolic activity and much longer preservation times than conventional cold storage. As usage of these newer systems grows, so will the demand for compatible, high-performance preservation solutions.

Yet, there are still challenges in the way of organ shortages and logistical issues. Even with Enhanced donor awareness and consent rates, the availability of viable organs continues to fall far short of increasing demand. Under such circumstances, the capacity to keep organs viable for longer periods and with increased viability can ensure optimal utilization of available organs, minimize wastage, and enhance transplant scheduling and matching procedures.

Growth opportunities are particularly robust in Asia-Pacific emerging markets, Latin America, and the Middle East. All these regions are witnessing increased investment in healthcare, better access to transplant centers, and supportive government policies that promote the growth of transplant volumes. Furthermore, international partnerships and public-private initiatives are contributing to the global standardization of best practices in organ preservation and procurement.

The organ preservation solutions market will have substantial growth by 2035. With the intersection of medical technology, policy, and increasing transplant demand, preservation innovations will increasingly determine the future of organ transplantation and save countless lives globally.

Report Attributes	Details
Organ Preservation Solutions Market Size (2025E)	USD 286.8 Million
Organ Preservation Solutions Market Size (2035F)	USD 574.7 Million
Global Market Growth Rate (2025 to 2035)	7.2% CAGR
China Industry Value (2025)	USD 38.84 million
U.S. Industry Value (2035)	USD 198.85 million
Key Companies Profiled	BioLife Solutions, Inc.; Essential Pharmaceuticals, LLC; Lifeline Scientific, Inc.; Preservation Solutions, Inc.; XVIVO Perfusion AB; Teva Pharmaceutical Industries Ltd.; Bridge to Life Ltd.; Accord Healthcare; OrganOx Limited; ToleroTech, Inc.; Claris Injectables Limited; Paragonix Technologies Inc.; BioTime, Inc.

Shifts in the Market from 2020 to 2024 and Future Trends 2025 to 2035

From 2020 to 2024, the organ preservation solutions market saw steady growth due to the rising number of organ transplant procedures and increased awareness of the importance of pre-transplant logistics. The market was largely ruled by products like the University of Wisconsin (UW) solution, histidine-tryptophan-ketoglutarate (HTK), and Celsior, which found common applications in kidney, liver, and heart preservation.

Government and charities advocated for better transplant facilities, while industry leaders like XVIVO Perfusion remained engaged in sustaining organ viability through hypothermic machine perfusion technologies. Breakthroughs based on minimal ischemic time and better graft function after transplantation were the highest priorities.

From 2025 to 2035, the industry will see breakthrough advancements, with a trend towards normothermic perfusion and cutting-edge bioengineered systems of preservation. The systems are being developed to imitate physiological conditions and improve organ viability beyond conventional boundaries.

The firms are spending money on intelligent preservation devices that will be able to monitor and analyze organ quality during transportation in real-time. In addition, greater cooperation between transplant centers and biotech firms is likely to drive innovations in organ preservation for composite tissues, pancreas, and lungs-beyond the conventional kidney and liver.

A Comparative Market Shift Analysis (2020 to 2024 vs. 2025 to 2035)

2020 to 2024	2025 to 2035
Growing organ transplant volumes, awareness, traditional solution effectiveness	Need for longer preservation, personalized medicine, and cross-border transplants.
UW solution, HTK, Celsior	Normothermic perfusion, oxygenated machine perfusion solutions
Targeting cold storage formulation and compatibility	Investment in intelligent perfusion technology, bioengineered and AI-imaged systems
Mitigating ischemic injury in transit	Optimization of real-time viability analysis with reduced organ wastage
Majorly kidneys, livers, hearts	Expansion to lungs, pancreas, and limb grafts
Static cold storage, low-perfusion	Dynamic perfusion, AI-driven organ status monitoring
Hospital and government collaborations	Biotech-transplant center collaborations for personalized, high-tech preservation

Organ Preservation Solutions Market: Forecast Analysis (2025 to 2035)

Country	Forecast CAGR (2025 to 2035)
U.S.	6.4%
UK	5.7%
France	5.2%
Germany	5.5%
Italy	4.9%
South Korea	6.0%
Japan	4.7%
China	7.1%
Australia	5.4%
New Zealand	4.6%

U.S.

The U.S. organ preservation solutions market is expected to grow at a CAGR of 6.4% during the period 2025 to 2035. The driving force behind the growth is predominantly due to increased demand for organ transplants, supported by robust infrastructure at advanced medical facilities.

Technical advancements in cold storage and perfusion procedures, particularly heart and lung transplants, are putting considerable demand on high-efficiency preservation solutions. The presence of well-known medical research institutions is also driving clinical advancement in organ preservation methods.

Leading industry players in the U.S., including XVIVO Perfusion, TransMedics, and OrganOx, are increasing R&D investment to enhance the efficacy and safety of preservation fluids. Collaborations with transplant centers and clinicians are making product testing easier and accelerating industry adoption.

The U.S. also continues to have beneficial regulatory systems that allow for accelerated product approval, which promotes faster commercialization of innovative organ preservation technology.

UK

The UK organ preservation solutions market is expected to grow at a CAGR of 5.7% during the forecast period. Increased awareness among the general population and a rise in the number of cases of organ failure are fueling increased transplantation programs in NHS-linked hospitals. Concern for optimizing donor organ viability is fueling the uptake of both machine perfusion and static cold storage systems.

National biotechnology firms, as well as multinationals such as OrganOx and Bridge to Life, play a key role in introducing advances in preservation technology. Research work funded by the state stimulates developments in normothermic preservation, particularly of kidney and liver transplant organs. In the UK, a framework is in place to guide facilitated integration among practice and research and assist in the ease of adoption and upscaling by top-run transplant units.

France

The French organ preservation solutions market is expected to register a CAGR of 5.2% during the period 2025 to 2035. Increased organ donation rates, along with policy changes at the national level, are driving demand for effective preservation systems. Established organ transplant centers in the nation enable sustained use of preservation fluids for extended storage durations.

Technology innovations in preservation processes, including hypothermic and normothermic perfusion, are being triggered by strategic alliances between biotech firms and government hospitals. Companies like France's MedXpert and other suppliers in Europe are expanding product portfolios to meet detailed clinical needs. Enhanced training directives and focus on organ viability maximization are also influencing adoption behaviors in the French healthcare industry.

Germany

Germany is forecasted to have a CAGR of 5.5% over the 2025 to 2035 period for the organ preservation solutions market. Strategies to promote donor registrations initiated by the government are supplemented by rising end-stage organ diseases and expanding growth. The national emphasis on healthcare innovation is increasing the application of novel preservation solutions in academic as well as clinical institutions.

Key leaders such as Dr. Franz Köhler Chemie and international competitors are investing in organ-specific fluids to address transplantation complexity. A centralized healthcare system in Germany allows systematic distribution and monitoring of organ preservation products. Continuous interaction between transplant surgeons and biotech developers is driving the development of ex vivo organ management technology.

Italy

Italy's organ preservation solutions market is expected to grow at 4.9% CAGR between 2025 and 2035. Demand growth is fueled by the growing number of organ transplant procedures facilitated by local healthcare networks and improved donor-recipient matching systems. Cold storage dominates by far, but shifting interest in dynamic preservation technology is on the rise.

Local healthcare institutions are increasingly adopting perfusion-based preservation methods for greater graft viability. Companies such as America, in collaboration with international partners, are introducing tailored solutions for kidney and liver preservation. Donor shortages are driving innovation in optimizing organ viability, consolidating the role of high-performance preservation fluids.

South Korea

South Korea will record a CAGR of 6.0% during the forecast period in the organ preservation solutions market. Growing chronic organ failure rates, along with an increasing medical tourism sector, are driving demand for sophisticated preservation technologies. Academic medical centers are central to the research and development of innovative preservation techniques.

Companies like Genewel and CJ HealthCare are making preservation solutions available locally for Asian transplant protocols. Medical biotechnology and regulatory incentives are encouraging government investment, along with faster clinical trials and commercial implementation. Smart monitoring systems coming together with machine perfusion equipment are expected to enhance the accuracy of organ preservation in South Korean healthcare facilities.

Japan

The Japan organ preservation solutions market is anticipated to record a CAGR of 4.7% from 2025 to 2035. The increasing prevalence of liver and kidney diseases is fueling transplant procedures, which in turn leads to the growing demand for preservation fluids. While traditional static storage is still dominant, Japan is increasingly embracing perfusion technologies as part of its transplant scenario.

Leading drug companies, like Terumo and Otsuka Pharmaceutical, are investing in leading-edge preservation products and expanding product accessibility with nationwide distribution systems. Official programs to revise transplantation law are complementing private industry. Concern for post-transplant outcomes is shaping product selection criteria, particularly in multi-organ preservation.

China

China is anticipated to grow at 7.1% CAGR during the study period. An increasingly emerging health system, combined with rising organ transplant procedures, is creating astounding opportunities for preservation methods of the future. Investments at the national level in modernizing transplant facilities are driving hospitals' enhanced capabilities.

Domestic players such as TransMed China and Sinopharm are propelling the development and commercialization of basic and higher-end preservation solutions. The incorporation of machine perfusion in tertiary care hospitals is improving clinical outcomes, particularly for heart and liver transplants. Ongoing regulatory reforms are giving a positive impetus to both domestic and international manufacturers. They are introducing next-generation preservation products.

Australia

The organ preservation solutions market in Australia will reach a CAGR of 5.4% between 2025 and 2035. The rate of transplants is being stimulated through organ donation drives initiated by governments and increased awareness campaigns among citizens. Cold storage solutions are the most frequently applied, although expenditures on machine perfusion are increasingly common in the case of high-risk transplants.

Key leaders in the Australian organ preservation solutions market include biotechnology firms and overseas companies such as Organ Recovery Systems. Transplant research institutes partnering with healthcare professionals are making it easier for real-time preservation efficacy assessment. The increasing focus on enhancing graft survival rates is fuelling the use of newer preservation fluids and equipment.

New Zealand

New Zealand is projected to record a CAGR of 4.6% in the organ preservation solutions market through the forecast period. There is a moderate but steadily growing volume of transplant surgeries driving focused demand for advanced quality preservation technology. National healthcare administrations apply set procedures for the storage and transport of organs.

Offshore suppliers dominate the supply of products in New Zealand and are supported by local distributors and health alliances. Clinical institutions are gradually introducing machine-based preservation systems to improve organ viability. Attempts to optimize transplant readiness and optimize donor organ utilization are facilitating the convergence of new preservation methods.

Segment-wise Analysis

By Technique

Due to advancements in transplantation techniques and the increasing global need for viable donor organs, the static cold storage segment is poised to hold a share of 45.1% in 2025. The SCS is considered the standard method of organ preservation for its simplicity, cost-friendliness, and widespread availability.

It involves the immersion of donor organs in a preservation solution at reduced temperatures to minimize metabolic activity and further cellular degradation. In this regard, solutions such as the University of Wisconsin solution and Custodial HTK manufactured by Bridge to Life Ltd., Dr. Franz Köhler Chemie GmbH, and Preservation Solutions Inc. are often applied in the technique. SCS is especially effective in organ preservation, particularly kidneys, liver, and pancreas, for short- to moderate-term.

In parallel, hypothermic machine perfusion (HMP) will be rapidly adopted in 2025 and will represent an estimated share volume of 35%. Unlike SCS, HMP involves continuous perfusion of the organ with a cold preservation solution that sustains tissue viability and, therefore, allows for functional assessment before transplantation.

This method of organ preservation has been shown to help attenuate delayed graft function and improve long-term transplant outcomes, especially in the case of marginal or extended criteria donor organs. The industry was pioneered by Organ Recovery Systems and XVIVO Perfusion AB with the LifePort Kidney Transporter and the PERFUSIX system, respectively. With mounting clinical evidence favoring HMP, especially in high-income healthcare systems, the uptake of HMP is likely to spread to liver and heart organ preservation as well.

SCS is expected to dominate due to costs and convenience; however, HMP is anticipated to have faster growth due to its clinical advantages, with a growing trend towards application in transplant centers focused on improving outcomes for challenging donor organs.

By Organ Type

For the year 2025, the organ preservation solutions market is segmented organ-wise, with kidneys accounting for the largest contribution of about 34.5%. The reason for the maximum contribution is that kidney transplants have a high global volume as the most frequently performed transplant in the world due to end-stage renal disease (ESRD).

The other established preservation methods, like Static Cold Storage (SCS) and the increasing use of Hypothermic Machine Perfusion (HMP), have strongly promoted the success rates of kidney transplants. Organ Recovery Systems and Bridge to Life Ltd. are widely used providers of such perfusion systems and solutions for renal preservation; LifePort Kidney Transporter and UW solution are both considered the standard of care in many regions.

The liver segment will represent about 25% of the share by 2025. Liver transplantation is a complex and resource-intensive procedure where the viability of the liver must be preserved from the donor to the recipient, especially for marginal or extended criteria donor livers.

All this causes a greater reliance on dynamic preservation methods, both hypothermic and normothermic machine perfusion, to help maintain hepatocellular function and enable viability assessment before transplantation. Examples of such companies include XVIVO Perfusion AB, the PERFUSIX Liver system, and TransMedics, which provides the Organ Care System (OCS).

The necessity for organ-specific good preservation solutions will become ever more pressing as transplant demand continues to rise around the world. In contrast, healthcare systems continue to struggle with their respective organ discard rates. Both the kidney and the liver will witness advances in organ preservation technology that will be rapid and specific to the innovations occurring in perfusion systems and solution improvements.

Competitive Outlook

The organ preservation solutions market is competitively structured, with leading players intent on maximizing preservation efficacy, viability of organs, and ultimately, success rates of transplants. Following in-house developed preservation solutions for various types of organs, mainly the kidney, liver, and heart, the companies integrate cryopreservation and machine perfusion techniques. Competitive differentiation is further enhanced by strategic partnerships with transplant centers, along with advancements in regulations.

Innovations in preservation technologies are major defining factors, with leading companies investing in hypothermic as well as normothermic perfusion techniques for improving organ function before transplantation. Demand is also building for cell-based preservation solutions and optimized compositions of perfusates. Companies, apart from working on regulatory approvals and clinical validation for their techniques, are strengthening the industry's credibility to promote adoption.

Consolidation through mergers and acquisitions is another avenue frequently charted by the organ preservation solutions market, whereby major players acquire specialized firms to diversify as well as strengthen their array of preservation solutions. The companies also invest in giving a cold storage and machine perfusion solution suite to address different implant needs. Geographic expansion in emerging economies appears to be another strategy to meet the fast-growing demand for organ transplantation.

While pricing and distribution strategies diverge depending on the types of solutions offered, premium-priced preservation solutions with longer viability are clearly seen to lead the market. In contrast, cheaper static storage solutions are critical for accessibility. Large companies are apparently collaborating with major transplant hospitals and procurement organizations to develop partnerships to foster their sales. Recent entrants are focused on strengthening their foothold through low-cost alternatives and regional access.

Market Share Analysis by Company

Company Name	Estimated Market Share (%)
XVIVO Perfusion AB	20-25%
BioLife Solutions, Inc.	15-20%
Essential Pharmaceuticals, LLC	10-15%
Lifeline Scientific, Inc.	8-12%
Bridge to Life Ltd.	5-9%
Other Companies (combined)	30-40%

Key Company Offerings and Activities

Company Name	Key Offerings/Activities
XVIVO Perfusion AB	Specializes in normothermic and hypothermic perfusion solutions for extended organ viability.
BioLife Solutions, Inc.	Develop cryopreservation media and cell-based preservation solutions.
Essential Pharmaceuticals, LLC	Provides specialized solutions for kidney and liver preservation.
Lifeline Scientific, Inc.	Focuses on portable perfusion technology for organ transportation.
Bridge to Life Ltd.	Offers preservation solutions with an emphasis on machine perfusion.

Key Company Insights

XVIVO Perfusion AB (20-25%)

XVIVO Perfusion leads with advanced machine perfusion systems and a strong global presence in transplant solutions.

BioLife Solutions, Inc. (15-20%)

BioLife Solutions enhances organ and cell preservation with proprietary cryopreservation and biopreservation technologies.

Essential Pharmaceuticals, LLC (10-15%)

Essential Pharmaceuticals secures traction with specialized preservation solutions optimized for kidney and liver transplants.

Lifeline Scientific, Inc. (8-12%)

Lifeline Scientific advances portable perfusion devices to improve organ transport efficiency and increase transplant success rates.

Bridge to Life Ltd. (5-9%)

Bridge to Life Ltd. expands its portfolio with machine perfusion preservation techniques, strengthening its reach in transplant centers.

Other Key Players (30-40% Combined)

• Preservation Solutions, Inc.
• OrganOx Limited
• Teva Pharmaceutical Industries Ltd.
• Paragonix Technologies Inc.
• ToleroTech, Inc.

Key Players

• XVIVO Perfusion AB
• BioLife Solutions, Inc.
• Essential Pharmaceuticals, LLC
• Lifeline Scientific, Inc.
• Bridge to Life Ltd.
• Preservation Solutions, Inc.
• OrganOx Limited
• Teva Pharmaceutical Industries Ltd.
• Paragonix Technologies Inc.
• ToleroTech, Inc.
• Claris Injectables Limited
• Accord Healthcare

Segmentation

By Technique :

The segmentation is into static cold storage, hypothermic machine perfusion, normothermic machine perfusion, and others.

By Organ Type :

The segmentation is into kidneys, liver, lungs, heart, and others.

By End User :

The segmentation is into organ transplant centers, hospitals, and specialty clinics.

By Region :

The segmentation is into North America, Latin America, Europe, Asia Pacific, and Middle East and Africa (MEA).